Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover
NCT05151484Phase 4Active, not recruiting
- Start
- Mar 2022
- Primary completion
- Jan 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of teriparatide in osteoporosis (3 arms). Primary endpoints: Mineral Bone Density of the lumbar spine at 1 year and Measure of serum osteocalcin levels to predict bone turnover at 1 year. Started Mar 2022; status: active, not recruiting.
02
Drugs
teriparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT05151484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05151484.